Overview
Evidence on the impact of adverse events (AEs) on the many available first-line (1L) treatment options for locally advanced or metastatic urothelial cancer (la/mUC) —specifically rash, peripheral neuropathy (PN), and hyperglycemia (HG)—is limited. This study examined how often these adverse events occur, how they are managed, and their impact on la/mUC treatment.
While hospitalizations related to these AEs were uncommon, HG was associated with the highest hospitalization rate among the three, and importantly, no deaths were attributed to these AEs. The occurrence of these AEs often led to modifications in cancer treatment—including dose holds, dose reductions, or discontinuations— at differing rates depending on the 1L la/mUC regimen. Most patients who developed rash, PN, or HG also required targeted interventions to manage these side effects.
Why this matters
Understanding the management and impact of adverse events (AEs) on a patients’ ability to sustain cancer treatment is essential for enabling clinicians and patients to make informed cancer treatment decisions and supportive care plans. These findings underscore the value of considering drug safety profiles to optimize patient outcomes and reduce treatment disruptions.